The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Fedin A.V.

Zakharyin Clinical Hospital No. 6

Clinical observation of the course of eosinophilic otitis media against the background of biological therapy of chronic polypous rhinosinusitis

Authors:

Fedin A.V.

More about the authors

Journal: Russian Bulletin of Otorhinolaryngology. 2024;89(2): 95‑100

DOI: 10.17116/otorino20248902195

Read: 1575 times

Download PDF (RU)
Contact the author
Table of contents

CLINICAL OBSERVATION OF THE COURSE OF EOSINOPHILIC OTITIS MEDIA AGAINST THE BACKGROUND OF BIOLOGICAL THERAPY OF CHRONIC POLYPOUS RHINOSINUSITIS
CLINICAL OBSERVATION OF THE COURSE OF EOSINOPHILIC OTITIS MEDIA AGAINST THE BACKGROUND OF BIOLOGICAL THERAPY OF CHRONIC POLYPOUS RHINOSINUSITIS

To cite this article:

Fedin AV. Clinical observation of the course of eosinophilic otitis media against the background of biological therapy of chronic polypous rhinosinusitis. Russian Bulletin of Otorhinolaryngology. 2024;89(2):95‑100. (In Russ.)
https://doi.org/10.17116/otorino20248902195

Подписка 2026 Вестник оториноларингологии (Russian Bulletin of Otorhinolaryngology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Immu­notherapy in the treatment of chro­nic poly­pous rhinosinusitis with como­rbid bronchial asthma. Russian Bulletin of Otorhinolaryngology. 2025;(1):29-34
Clinical case: the effe­ctiveness of gene­tically engi­neered biological therapy in a patient with orbi­tal wall defe­cts caused by chro­nic poly­posis rhinosinusitis. Russian Bulletin of Otorhinolaryngology. 2025;(5):108-112
Effi­cacy of dupi­lumab application in bullous pemphigoid proceeding in presence of bronchial asthma. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(2):204-209
Syne­rgistic effi­ciency of preformed physical factors and dupi­lumab in the treatment of poly­pous rhinosinusitis. Rege­nerative Biotechnologies, Preventive, Digi­tal and Predictive Medi­cine. 2025;(2):16-23
Rela­tionship between oxidative stress patterns and proinflammatory cyto­kines in patients with poly­pous rhinosinusitis under the course of therapeutic physical factors. Rege­nerative Biotechnologies, Preventive, Digi­tal and Predictive Medi­cine. 2025;(2):42-49
Labo­ratory considerations in asse­ssing effi­cacy and safety of biologic therapy in the elde­rly (as Exemplified by Asthma). Labo­ratory Service. 2025;(2):29-32
Clinical effi­cacy of dupi­lumab mono­clonal anti­body in the treatment of recu­rrent severe chro­nic rhinosinusitis with nasal polyps without bronchial asthma. Russian Rhinology. 2025;(4):32-37
Abstract:

RESUME

Eosinophilic otitis media (EoOM) is a variant of exudative otitis media characterized by a persistent persistent course, the presence of a very viscous effusion in the tympanic cavity, comorbidally associated with chronic polypous rhinosinusitis and bronchial asthma. The disease is characterized by a persistent progressive course, which can lead to a gradual decrease in hearing up to complete deafness. Conservative treatment methods for EoOM include local and systemic administration of glucocorticosteroids. Encouraging data on the effectiveness of biological therapy have appeared in recent publications. The above clinical observation examines the course of EoOM in a patient who received biological therapy with dupilamab.

Keywords:

eosinophilic otitis media
chronic polypous rhinosinusitis
dupilumab

Authors:

Fedin A.V.

Zakharyin Clinical Hospital No. 6

Received:

29.01.2024

Accepted:

01.03.2024

Close metadata

References:

  1. Seo Y, Nonaka M, Pawankar R. Eosinophilic otitis media and comorbid asthma. Current Opinion in Allergy and Clinical Immunology. 2020;20(1):9-13.  https://doi.org/10.1097/ACI.0000000000000589
  2. Iino Y. Eosinophilic otitis media; state-of-the-art diagnosis and treatment. Auris, Nasus, Larynx. 2023;50(4):479-489.  https://doi.org/10.1016/j.anl.2022.11.004
  3. Kosyakov SYa, Gunenkov AV. Eosinophilic otitis media is a disease associated with chronic polypous rhinosinusitis and bronchial asthma. Vestnik otorinolaringologii. 2013;78(5):80-83. (In Russ.).
  4. Tomioka S, Kobayashi T, Takasaka T. Intractable otitis media in patients with bronchial asthma. In: Sanna M, ed. Cholesteaioma and Mastoid Surgery. Rome, Italy: Edizioni Internazionali; 1997:851-853. 
  5. Nakagawa T, Matsubara A, Shiratsuchi H, Kakazu Y, Nakashima T, Koike K, Umezaki T, Komune S. Intractable Otitis Media with Eosinophils: Importance of Diagnosis and Validity of Treatment for Hearing Preservation. ORL ORL; Journal for Oto-Rhino-Laryngology and its Related Specialties. 2006;68(2):118-122. 
  6. Iino Y, Tomioka-Matsutani S, Matsubara A, Nakagawa T, Nonaka M. Diagnostic criteria of eosinophilic otitis media, a newly recognized middle ear disease. Auris, Nasus, Larynx. 2011;38(4):456-461.  https://doi.org/10.1016/j.anl.2010.11.016
  7. Iino Y, Usubuchi H, Kodama K, Takizawa K, Kanazawa T, Ohta Y. Bone conduction hearing level in patients with eosinophilic otitis media associated with bronchial asthma. Otology and Neurotology. 2008;29(7):949-952.  https://doi.org/10.1097/MAO.0b013e318185fb0d
  8. Iino Y, Nagamine H, Yabe T, Matsutani S. Eosinophils are activated in middle ear mucosa and middle ear eff usion of patients with intractable otitis media associated with bronchial asthma. Clinical and Experimental Allergy. 2001;31(7):1135-1143. https://doi.org/10.1046/j.1365-2222.2001.01134.x
  9. Nagamine H, Iino Y, Kojima C, Miyazawa T, Iida T. Clinical characteristics of socalled eosinophilic otltis media. Auris, Nasus, Larynx. 2002;29(1):19-28.  https://doi.org/10.1016/s0385-8146(01)00124-9
  10. Iino Y, Kakizaki K, Katano H, Saigusa H, Kanegasaki S. Eosinophil chemoattractant in middle ear of patients with aosinophilic otitis media. Clinical and Experimental Allergy. 2005;35(10):1370-1376. https://doi.org/10.1111/j.1365-2222.2005.02330.x
  11. Iino Y, Nagamine H, Kakizaki K, Komiya T, Katano H, Saruya S, Kodera K. Effectiveness of instillation of triamcenolone acetonide into the middle ear for eosinophilic otitis media associated with bronchial asthma. Annals of Allergy, Asthma and Immunology. 2006;97(6):761-766.  https://doi.org/10.1016/S1081-1206(10)60967-2
  12. Yoshido N. Patulous eustachian tube develops the eosinophilic otitis media followed by chronic rhinosinusitis. Proceedings of the 9th International Conference on Cholesteatoma and Ear Surgery. Nagasaki, Japan; 2012:163. 
  13. Chen T, Ashman PE, Bojrab DI 2nd, Johnson AP, Hong RS, Benson B, Svider PF. Diagnosis and management of eosinophilic otitis media: a systematic review. Acta Oto-Laryngologica. 2021;141(6):579-587.  https://doi.org/10.1080/00016489.2021.1901985
  14. Tomioka S, Yuasa R, Iino Y. Intractable otitis media in cases with bronchial asthma. In: Mogi G, Honjo I, Ishii T, Takasaka T, eds. Recent Advances in Otitis Media, Proceedings of the Second Extraordinary International Symposium. Kugler. Amsterdam-New York; 1993:183-186. 
  15. Esu Y, Tamii S, Masuda M, Iino Y, Yoshida N. Effectiveness of myringoplasty in patients with eosinophilic otitis media. Auris, Nasus, Larynx. 2021;48(3):368-376.  https://doi.org/10.1016/j.anl.2020.09.005
  16. Iwasaki S, Nagura M, Mizuta K. Cochlear implantation in a patient with eosinophilic otitis media. European Archives of Oto-Rhino-Laryngology. 2006;263(4):365-369.  https://doi.org/10.1007/s00405-005-1006-2
  17. Robinson D, Humbert M, Buhl R, Cruz AA, Inoue H, Korom S, Hanania NA, Nair P. Revisiting Type 2-high and Type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. Clinical and Experimental Allergy. 2017;47(2):161-175.  https://doi.org/10.1111/cea.12880
  18. Gandhi NA, Bennett BL, Graham NM, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. Nature Reviews. Drug Discovery. 2016;15(1):35-50.  https://doi.org/10.1038/nrd4624
  19. De Vries IJ. The role of IL-13 and its receptor in allergy and inflammatory responses. Journal of Allergy and Clinical Immunology. 1998;102(3):461-468.  https://doi.org/10.1016/s0091-6749(98)70080-6
  20. Akdis CA, Arkwright PD, Brüggen MC, Busse W, Gadina M, Guttman-Yassky E, Kabashima K, Mitamura Y, Vian L, Wu J, Palomares O. Type 2 immunity in the skin and lungs. Allergy. 2020;75(7):1582-1605. https://doi.org/10.1111/all.14318
  21. Mezu-Ndubuisi OJ, Maheshwari A. The role of integrins in inflammation and angiogenesis. Pediatric Research. 2021;89(7):1619-1626. https://doi.org/10.1038/s41390-020-01177-9
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.